

1F-235-T025

Monoclonal Antibody to CD71 Fluorescein (FITC) conjugated (25 tests)

Clone: MEM-75

Isotype: Mouse IgG1

Specificity: The antibody MEM-75 reacts with CD71 antigen (transferrin receptor), a 95 kDa

type II homodimeric transmembrane glycoprotein expressed on activated B and T lymphocytes, macrophages and erythroid precursors; it is lost on resting blood

leukocytes.

The antibody MEM-75 does not block binding of transferrin to the receptor.

HLDA IV; WS Code A 45 HLDA V; WS Code T T-165

Regulatory Status: RUO

Immunogen: NALM-6 human pre-B cell line

Species Reactivity: Human

Preparation: The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under

optimum conditions. The reagent is free of unconjugated FITC and adjusted for

direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using

20 μl reagent / 100 μl of whole blood or 10^b cells in a suspension.

The content of a vial (0.5 ml) is sufficient for 25 tests.

Expiration: See vial label

Lot Number: See vial label

Background: CD71 (transferrin receptor) is a type II transmembrane glycoprotein expressed as

homodimer in erythroid blood cell line and in activated leukocytes. Upon binding of holotransferrin (complex of transferrin and iron ions), CD71 is internalized by clathrin-mediated endocytosis. Acidification of endosomes by vesicular membrane proton pumps leads to dissociation of iron ions, whereas transferrin (apotransferrin) remains associated with CD71 and recycles to the cell surface, where it is released upon exposure to normal pH. CD71 is also involved in uptake

of non-transferrin bound iron.



PRODUCT DATA SHEET

References:

*Rouault TA: How mammals acquire and distribute iron needed for oxygen-based metabolism. PLoS Biol. 2003 Dec;1(3):E79.

*Taketani S: Aquisition, mobilization and utilization of cellular iron and heme: endless findings and growing evidence of tight regulation. Tohoku J Exp Med. 2005 Apr;205(4):297-318.

*Graham RM, Chua AC, Herbison CE, Olynyk JK, Trinder D: Liver iron transport. World J Gastroenterol. 2007 Sep 21;13(35):4725-36.

*Graham RM, Reutens GM, Herbison CE, Delima RD, Chua AC, Olynyk JK, Trinder D: Transferrin receptor 2 mediates uptake of transferrin-bound and non-transferrin-bound iron. J Hepatol. 2008 Feb;48(2):327-34.

*Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).

*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995). *Beck Z, Balogh A, Kis A, Izsépi E, Cervenak L, László G, Bíró A, Liliom K, Mocsár G, Vámosi G, Füst G, Matko J: New cholesterol-specific antibodies remodel HIV-1 target cells' surface and inhibit their in vitro virus production. J Lipid Res. 2010 Feb;51(2):286-96.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.